GPR39 (Zinc Receptor) Knockout Mice Exhibit Depression-Like Behavior and CREB/BDNF Down-Regulation in the Hippocampus

Background:Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.Methods:In the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like behavior, as measured by the forced swim test, tail suspe...

Full description

Saved in:

Bibliographic Details
Published in:	The international journal of neuropsychopharmacology Vol. 18; no. 3; pp. 1 - 8
Main Authors:	Młyniec, Katarzyna, Budziszewska, Bogusława, Holst, Birgitte, Ostachowicz, Beata, Nowak, Gabriel
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 01.02.2015
Subjects:	Animals Anxiety Brain-derived neurotrophic factor Brain-Derived Neurotrophic Factor - metabolism Corticosterone - blood CREB-Binding Protein - metabolism Dark Adaptation - genetics Depression - genetics Depression - metabolism Depression - pathology Disease Models, Animal Down-Regulation - genetics Hindlimb Suspension Hippocampus - metabolism Hypothalamus Immobility Response, Tonic - physiology Kinases Male Mental depression Mice Mice, Inbred C57BL Mice, Knockout Motor Activity - genetics Proteins Receptor, trkB - metabolism Receptors, G-Protein-Coupled - deficiency Receptors, G-Protein-Coupled - genetics Swimming - psychology Time Factors Zinc - metabolism GPR39 HPA axis CREB depression zinc receptor
ISSN:	1461-1457, 1469-5111, 1469-5111
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Background:Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.Methods:In the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like behavior, as measured by the forced swim test, tail suspension test, and light/dark test. We also investigated whether lack of GPR39 would change levels of cAMP response element-binding protein (CREB),brain-derived neurotrophic factor (BDNF) and tropomyosin related kinase B (TrkB) protein in the hippocampus and frontal cortex of GPR39 knockout mice subjected to the forced swim test, as measured by Western-blot analysis.Results:In this study, GPR39 knockout mice showed an increased immobility time in both the forced swim test and tail suspension test, indicating depressive-like behavior and displayed anxiety-like phenotype. GPR39 knockout mice had lower CREB and BDNF levels in the hippocampus, but not in the frontal cortex, which indicates region specificity for the impaired CREB/BDNF pathway (which is important in antidepressant response) in the absence of GPR39. There were no changes in TrkB protein in either structure. In the present study, we also investigated activity in the hypothalamus-pituitary-adrenal axis under both zinc- and GPR39-deficient conditions. Zinc-deficient mice had higher serum corticosterone levels and lower glucocorticoid receptor levels in the hippocampus and frontal cortex.Conclusions:There were no changes in the GPR39 knockout mice in comparison with the wild-type control mice, which does not support a role of GPR39 in hypothalamus-pituitary-adrenal axis regulation. The results of this study indicate the involvement of the GPR39 Zn2+-sensing receptor in the pathophysiology of depression with component of anxiety.
AbstractList	Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors. In the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like behavior, as measured by the forced swim test, tail suspension test, and light/dark test. We also investigated whether lack of GPR39 would change levels of cAMP response element-binding protein (CREB),brain-derived neurotrophic factor (BDNF) and tropomyosin related kinase B (TrkB) protein in the hippocampus and frontal cortex of GPR39 knockout mice subjected to the forced swim test, as measured by Western-blot analysis. In this study, GPR39 knockout mice showed an increased immobility time in both the forced swim test and tail suspension test, indicating depressive-like behavior and displayed anxiety-like phenotype. GPR39 knockout mice had lower CREB and BDNF levels in the hippocampus, but not in the frontal cortex, which indicates region specificity for the impaired CREB/BDNF pathway (which is important in antidepressant response) in the absence of GPR39. There were no changes in TrkB protein in either structure. In the present study, we also investigated activity in the hypothalamus-pituitary-adrenal axis under both zinc- and GPR39-deficient conditions. Zinc-deficient mice had higher serum corticosterone levels and lower glucocorticoid receptor levels in the hippocampus and frontal cortex. There were no changes in the GPR39 knockout mice in comparison with the wild-type control mice, which does not support a role of GPR39 in hypothalamus-pituitary-adrenal axis regulation. The results of this study indicate the involvement of the GPR39 Zn(2+)-sensing receptor in the pathophysiology of depression with component of anxiety. Background:Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.Methods:In the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like behavior, as measured by the forced swim test, tail suspension test, and light/dark test. We also investigated whether lack of GPR39 would change levels of cAMP response element-binding protein (CREB),brain-derived neurotrophic factor (BDNF) and tropomyosin related kinase B (TrkB) protein in the hippocampus and frontal cortex of GPR39 knockout mice subjected to the forced swim test, as measured by Western-blot analysis.Results:In this study, GPR39 knockout mice showed an increased immobility time in both the forced swim test and tail suspension test, indicating depressive-like behavior and displayed anxiety-like phenotype. GPR39 knockout mice had lower CREB and BDNF levels in the hippocampus, but not in the frontal cortex, which indicates region specificity for the impaired CREB/BDNF pathway (which is important in antidepressant response) in the absence of GPR39. There were no changes in TrkB protein in either structure. In the present study, we also investigated activity in the hypothalamus-pituitary-adrenal axis under both zinc- and GPR39-deficient conditions. Zinc-deficient mice had higher serum corticosterone levels and lower glucocorticoid receptor levels in the hippocampus and frontal cortex.Conclusions:There were no changes in the GPR39 knockout mice in comparison with the wild-type control mice, which does not support a role of GPR39 in hypothalamus-pituitary-adrenal axis regulation. The results of this study indicate the involvement of the GPR39 Zn2+-sensing receptor in the pathophysiology of depression with component of anxiety. Background: Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors. Methods: In the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like behavior, as measured by the forced swim test, tail suspension test, and light/dark test. We also investigated whether lack of GPR39 would change levels of cAMP response element-binding protein (CREB), brain-derived neurotrophic factor (BDNF) and tropomyosin related kinase B (TrkB) protein in the hippocampus and frontal cortex of GPR39 knockout mice subjected to the forced swim test, as measured by Western-blot analysis. Results: In this study, GPR39 knockout mice showed an increased immobility time in both the forced swim test and tail suspension test, indicating depressive-like behavior and displayed anxiety-like phenotype. GPR39 knockout mice had lower CREB and BDNF levels in the hippocampus, but not in the frontal cortex, which indicates region specificity for the impaired CREB/BDNF pathway (which is important in antidepressant response) in the absence of GPR39. There were no changes in TrkB protein in either structure. In the present study, we also investigated activity in the hypothalamus-pituitary-adrenal axis under both zinc- and GPR39-deficient conditions. Zinc-deficient mice had higher serum corticosterone levels and lower glucocorticoid receptor levels in the hippocampus and frontal cortex. Conclusions: There were no changes in the GPR39 knockout mice in comparison with the wild-type control mice, which does not support a role of GPR39 in hypothalamus-pituitary-adrenal axis regulation. The results of this study indicate the involvement of the GPR39 Zn super(2+)-sensing receptor in the pathophysiology of depression with component of anxiety. Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.BACKGROUNDZinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.In the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like behavior, as measured by the forced swim test, tail suspension test, and light/dark test. We also investigated whether lack of GPR39 would change levels of cAMP response element-binding protein (CREB),brain-derived neurotrophic factor (BDNF) and tropomyosin related kinase B (TrkB) protein in the hippocampus and frontal cortex of GPR39 knockout mice subjected to the forced swim test, as measured by Western-blot analysis.METHODSIn the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like behavior, as measured by the forced swim test, tail suspension test, and light/dark test. We also investigated whether lack of GPR39 would change levels of cAMP response element-binding protein (CREB),brain-derived neurotrophic factor (BDNF) and tropomyosin related kinase B (TrkB) protein in the hippocampus and frontal cortex of GPR39 knockout mice subjected to the forced swim test, as measured by Western-blot analysis.In this study, GPR39 knockout mice showed an increased immobility time in both the forced swim test and tail suspension test, indicating depressive-like behavior and displayed anxiety-like phenotype. GPR39 knockout mice had lower CREB and BDNF levels in the hippocampus, but not in the frontal cortex, which indicates region specificity for the impaired CREB/BDNF pathway (which is important in antidepressant response) in the absence of GPR39. There were no changes in TrkB protein in either structure. In the present study, we also investigated activity in the hypothalamus-pituitary-adrenal axis under both zinc- and GPR39-deficient conditions. Zinc-deficient mice had higher serum corticosterone levels and lower glucocorticoid receptor levels in the hippocampus and frontal cortex.RESULTSIn this study, GPR39 knockout mice showed an increased immobility time in both the forced swim test and tail suspension test, indicating depressive-like behavior and displayed anxiety-like phenotype. GPR39 knockout mice had lower CREB and BDNF levels in the hippocampus, but not in the frontal cortex, which indicates region specificity for the impaired CREB/BDNF pathway (which is important in antidepressant response) in the absence of GPR39. There were no changes in TrkB protein in either structure. In the present study, we also investigated activity in the hypothalamus-pituitary-adrenal axis under both zinc- and GPR39-deficient conditions. Zinc-deficient mice had higher serum corticosterone levels and lower glucocorticoid receptor levels in the hippocampus and frontal cortex.There were no changes in the GPR39 knockout mice in comparison with the wild-type control mice, which does not support a role of GPR39 in hypothalamus-pituitary-adrenal axis regulation. The results of this study indicate the involvement of the GPR39 Zn(2+)-sensing receptor in the pathophysiology of depression with component of anxiety.CONCLUSIONSThere were no changes in the GPR39 knockout mice in comparison with the wild-type control mice, which does not support a role of GPR39 in hypothalamus-pituitary-adrenal axis regulation. The results of this study indicate the involvement of the GPR39 Zn(2+)-sensing receptor in the pathophysiology of depression with component of anxiety.
Author	Holst, Birgitte Młyniec, Katarzyna Ostachowicz, Beata Budziszewska, Bogusława Nowak, Gabriel
Author_xml	– sequence: 1 givenname: Katarzyna surname: Młyniec fullname: Młyniec, Katarzyna organization: Department of Biochemical Toxicology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Dr. K. Młyniec, Prof. B. Budziszewska); Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31–343 Kraków, Poland (Profs. B. Budziszewska, G. Nowak); Department of Neuroscience and Pharmacology University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen, Denmark (Prof. B. Holst); Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Kraków, Poland (Dr. B. Ostachowicz); Department of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Prof. G. Nowak) – sequence: 2 givenname: Bogusława surname: Budziszewska fullname: Budziszewska, Bogusława organization: Department of Biochemical Toxicology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Dr. K. Młyniec, Prof. B. Budziszewska); Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31–343 Kraków, Poland (Profs. B. Budziszewska, G. Nowak); Department of Neuroscience and Pharmacology University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen, Denmark (Prof. B. Holst); Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Kraków, Poland (Dr. B. Ostachowicz); Department of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Prof. G. Nowak) – sequence: 3 givenname: Birgitte surname: Holst fullname: Holst, Birgitte organization: Department of Biochemical Toxicology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Dr. K. Młyniec, Prof. B. Budziszewska); Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31–343 Kraków, Poland (Profs. B. Budziszewska, G. Nowak); Department of Neuroscience and Pharmacology University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen, Denmark (Prof. B. Holst); Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Kraków, Poland (Dr. B. Ostachowicz); Department of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Prof. G. Nowak) – sequence: 4 givenname: Beata surname: Ostachowicz fullname: Ostachowicz, Beata organization: Department of Biochemical Toxicology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Dr. K. Młyniec, Prof. B. Budziszewska); Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31–343 Kraków, Poland (Profs. B. Budziszewska, G. Nowak); Department of Neuroscience and Pharmacology University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen, Denmark (Prof. B. Holst); Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Kraków, Poland (Dr. B. Ostachowicz); Department of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Prof. G. Nowak) – sequence: 5 givenname: Gabriel surname: Nowak fullname: Nowak, Gabriel organization: Department of Biochemical Toxicology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Dr. K. Młyniec, Prof. B. Budziszewska); Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31–343 Kraków, Poland (Profs. B. Budziszewska, G. Nowak); Department of Neuroscience and Pharmacology University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen, Denmark (Prof. B. Holst); Faculty of Physics and Applied Computer Science, AGH University of Science and Technology, Kraków, Poland (Dr. B. Ostachowicz); Department of Pharmacobiology, Jagiellonian University Medical College, Medyczna 9, PL 30–688 Kraków, Poland (Prof. G. Nowak)
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25609596$$D View this record in MEDLINE/PubMed
BookMark	eNqFkstv1DAQxi1URB9w4o4sIaGiKqwdx876Uol9tEUsD63gwsVynEnX26wd4rjQ_75ut1RQCTh5JP_m0zffzD7acd4BQs8peUOJZCO7dt2ou4qE5I_QHi2EzDildOe2phkteLmL9kNYJ6DgTDxBuzkXRHIp9lA8_bxkEh9-s87gJRjoBt-_xu-dNxc-DviDNYDnP1e2sgOeQddDCNa7bGEvAE9gpS-t77F2NZ4u55PRZPbxBM_8D5ct4Ty2ekgstg4PK8Bntuu80ZsuhqfocaPbAM_u3gP09WT-ZXqWLT6dvpu-XWQm-Ruyum6qRlIhCgJCF6ZhMq9qyeu8BsnGRlYCmpqRhhJdNmnocsxyRkpGiRCggR2g461uF6sN1Abc0OtWdb3d6P5KeW3Vnz_OrtS5v1QFEykskQQO7wR6_z1CGNTGBgNtqx34GBQtBZclyWX5f1RwnnIXkif05QN07WPvUhKK0ZLQnI8FSdSL383fu_61vAQcbQHT-xB6aO4RStTNaaib01Db00g0fUAbO9wuKE1u27_0vNr2-Nj9U_waZg3Kgg
CitedBy_id	crossref_primary_10_2147_JEP_S531431 crossref_primary_10_3389_fnut_2024_1453064 crossref_primary_10_1186_s12993_024_00254_x crossref_primary_10_3390_ijms22083872 crossref_primary_10_1007_s11011_021_00839_9 crossref_primary_10_1016_j_bbr_2015_03_053 crossref_primary_10_1016_j_bbr_2021_113647 crossref_primary_10_1007_s40263_022_00984_4 crossref_primary_10_1016_j_neuropharm_2021_108752 crossref_primary_10_3389_fncel_2022_893030 crossref_primary_10_1016_j_intimp_2024_113491 crossref_primary_10_1002_ardp_70018 crossref_primary_10_1080_15384101_2018_1556060 crossref_primary_10_1016_j_brainresbull_2015_04_005 crossref_primary_10_3390_ijms22158200 crossref_primary_10_1016_j_biopha_2017_12_056 crossref_primary_10_1016_j_pharep_2015_04_003 crossref_primary_10_1007_s11011_018_0295_2 crossref_primary_10_1016_j_neuroscience_2022_09_002 crossref_primary_10_1093_nutrit_nuad076 crossref_primary_10_1016_j_jneuroim_2015_12_001 crossref_primary_10_1007_s12035_016_9870_x crossref_primary_10_1186_s40035_016_0070_4 crossref_primary_10_3389_fnins_2020_582853 crossref_primary_10_1016_j_phymed_2016_02_009 crossref_primary_10_1016_j_ejphar_2018_07_045 crossref_primary_10_1016_j_jad_2020_03_137 crossref_primary_10_1016_j_bbadis_2015_09_003 crossref_primary_10_1016_j_pharep_2017_01_010 crossref_primary_10_1155_2017_3682752 crossref_primary_10_1016_j_biopha_2023_114951 crossref_primary_10_1038_srep33694 crossref_primary_10_1007_s12011_016_0679_2 crossref_primary_10_1016_j_cytogfr_2016_08_004 crossref_primary_10_1016_j_pbb_2017_08_003 crossref_primary_10_1016_j_brainres_2023_148577 crossref_primary_10_1111_cns_14174 crossref_primary_10_3389_fphar_2017_00414 crossref_primary_10_1016_j_pharep_2015_10_006 crossref_primary_10_1016_j_intimp_2017_05_036 crossref_primary_10_3390_ijms18112334 crossref_primary_10_1016_j_jad_2016_05_007 crossref_primary_10_4103_1673_5374_193238 crossref_primary_10_1007_s12035_023_03891_x
Cites_doi	10.1016/j.physbeh.2008.06.017 10.1016/S0006-3223(96)00365-4 10.1097/01.wnr.0000215779.76602.93 10.1017/S1461145713001119 10.1016/j.pnpbp.2010.02.010 10.1210/en.2008-1250 10.1007/s00018-010-0517-1 10.2165/11599770-000000000-00000 10.1016/j.biopsych.2013.05.008 10.1016/S0193-953X(05)70283-5 10.1017/S1461145713000485 10.1016/S1734-1140(13)71512-3 10.1001/archpsyc.60.8.804 10.1016/j.pharep.2014.03.001 10.1007/s00726-008-0195-6 10.1523/JNEUROSCI.5093-08.2009 10.1016/S1734-1140(12)70762-4 10.1039/c2mt20018j 10.1016/j.bbr.2012.10.020 10.1176/appi.ajp.2007.06111868 10.1016/j.neubiorev.2013.03.018 10.1017/S1461145706007231 10.1016/j.pnpbp.2005.08.006 10.1016/S1734-1140(12)70852-6 10.1016/j.coph.2012.07.019 10.1210/me.2007-0055 10.1016/S1734-1140(13)71035-1 10.1007/s12640-010-9206-y 10.1016/j.neures.2011.12.002 10.1016/j.neuropharm.2013.12.001 10.1038/nrn1671 10.1080/10799890701506147 10.3389/fphar.2013.00161 10.1016/j.neuint.2009.11.014 10.1007/s00726-001-0121-7 10.1016/j.neuropharm.2004.08.010 10.1016/j.tips.2009.09.002 10.1074/jbc.M407676200 10.1523/JNEUROSCI.2205-11.2011 10.1192/bjp.184.5.386 10.1016/j.neuint.2009.05.011 10.1016/j.biopsych.2013.01.021 10.1006/geno.1997.5069 10.1016/S0165-0327(99)00011-7 10.1017/S1461145711001386 10.1210/en.2006-0933 10.1016/j.neuint.2013.02.024
ContentType	Journal Article
Copyright	The Author 2015. Published by Oxford University Press on behalf of CINP. 2015 The Author 2015. Published by Oxford University Press on behalf of CINP. The Author 2015. Published by Oxford University Press on behalf of CINP. This work is published under http://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author 2015. Published by Oxford University Press on behalf of CINP. 2015 – notice: The Author 2015. Published by Oxford University Press on behalf of CINP. – notice: The Author 2015. Published by Oxford University Press on behalf of CINP. This work is published under http://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	TOX AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M1P M2M PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 7TK 5PM
DOI	10.1093/ijnp/pyu002
DatabaseName	Oxford Journals Open Access Collection CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Psychology Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Neurosciences Abstracts PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Neurosciences Abstracts
DatabaseTitleList	MEDLINE Publicly Available Content Database Neurosciences Abstracts MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1469-5111
EndPage	8
ExternalDocumentID	PMC4360246 25609596 10_1093_ijnp_pyu002 10.1093/ijnp/pyu002
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -E. .FH 0E1 0R~ 123 29J 4.4 5VS 74X 74Y 7~V 8R4 8R5 AAFWJ AAMVS AAOGV AAPPN AAPXW AAVAP ABEJV ABGNP ABITZ ABIVO ABKKG ABPTD ABQLI ABVKB ABXVV ACGFS ACIMK ADBBV ADHZD ADRAZ AEMTW AENEX AENZO AFFVI AFULF AFUTZ AHMBA AJ7 ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQC AMNDL AOIJS ARABE AVWKF BAWUL BAYMD BCNDV BTTYL C0O CIDKT CS3 DC4 DIK DU5 EBS EJD EMOBN GROUPED_DOAJ H13 HG- HST HYE HZ~ I.6 I~P J36 J38 J3A KQ8 KSI L98 M-V M48 ML0 M~E O9- OAWHX OJQWA OK1 P2P PEELM Q2X RHF ROL ROX RPM RR0 S6- S70 TJX TOX TUQ UU6 WQ3 WXU WYP 0VX 53G 7X7 88E 8AO 8FI 8FJ AAYXX ABUWG AFFHD AFKRA AFPKN AZQEC BENPR BPHCQ BVXVI CAG CCPQU CITATION COF DWQXO FYUFA GNUQQ HMCUK IAO IHR ITC M1P M2M PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ UKHRP CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 7TK 5PM
ID	FETCH-LOGICAL-c609t-ddfbf916640e6a4cf392bd95d2de938c9b6efd30f10a7f511783230731066eae3
IEDL.DBID	BENPR
ISICitedReferencesCount	72
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000352535900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1461-1457 1469-5111
IngestDate	Tue Nov 04 01:54:20 EST 2025 Thu Oct 02 03:01:26 EDT 2025 Thu Oct 02 09:46:17 EDT 2025 Mon Oct 06 18:35:21 EDT 2025 Mon Jul 21 06:02:08 EDT 2025 Sat Nov 29 06:00:44 EST 2025 Tue Nov 18 22:39:55 EST 2025 Tue Feb 04 08:58:34 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	GPR39 HPA axis CREB depression zinc receptor
Language	English
License	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com The Author 2015. Published by Oxford University Press on behalf of CINP.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c609t-ddfbf916640e6a4cf392bd95d2de938c9b6efd30f10a7f511783230731066eae3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://www.proquest.com/docview/3170125860?pq-origsite=%requestingapplication%
PMID	25609596
PQID	3170125860
PQPubID	43629
PageCount	8
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_4360246 proquest_miscellaneous_1765970297 proquest_miscellaneous_1655256695 proquest_journals_3170125860 pubmed_primary_25609596 crossref_primary_10_1093_ijnp_pyu002 crossref_citationtrail_10_1093_ijnp_pyu002 oup_primary_10_1093_ijnp_pyu002
PublicationCentury	2000
PublicationDate	2015-02-01
PublicationDateYYYYMMDD	2015-02-01
PublicationDate_xml	– month: 02 year: 2015 text: 2015-02-01 day: 01
PublicationDecade	2010
PublicationPlace	US
PublicationPlace_xml	– name: US – name: England – name: Oxford
PublicationTitle	The international journal of neuropsychopharmacology
PublicationTitleAlternate	Int J Neuropsychopharmacol
PublicationYear	2015
Publisher	Oxford University Press
Publisher_xml	– name: Oxford University Press
References	Yasuda ( key 20170523182026_CIT0051) (2014); 9893 Maes ( key 20170523182026_CIT0020) (1999); 56 Pilc ( key 20170523182026_CIT0032) (2013); 73 Whittle ( key 20170523182026_CIT0049) (2009); 36 Młyniec ( key 20170523182026_CIT0027) 2014; 4 Skolnick ( key 20170523182026_CIT0040) (2009); 30 Tamano ( key 20170523182026_CIT0045) (2009); 55 Młyniec ( key 20170523182026_CIT0026) 2013; 238 Takeda ( key 20170523182026_CIT0044) (2012); 4 Besser ( key 20170523182026_CIT0001) (2009); 29 Ustun ( key 20170523182026_CIT0047) (2004); 184 Pochwat ( key 20170523182026_CIT0033) (2014) Frederickson ( key 20170523182026_CIT0009) (2005); 6 Swardfager ( key 20170523182026_CIT0041) 2013; 74 Fava ( key 20170523182026_CIT0007) (1996); 19 Młyniec ( key 20170523182026_CIT0024) (2012); 64 Herman ( key 20170523182026_CIT0012) (2005); 29 Yasuda ( key 20170523182026_CIT0050) (2007); 27 Egerod ( key 20170523182026_CIT0006) (2007); 21 Młyniec ( key 20170523182026_CIT0028) 2014; 79 Singewald ( key 20170523182026_CIT0037) (2004); 47 Siwek ( key 20170523182026_CIT0038) (2013); 65 Holst ( key 20170523182026_CIT0013) (2004); 279 Pandey ( key 20170523182026_CIT0031) (2007); 10 Haile ( key 20170523182026_CIT0011) (2014); 17 Browne ( key 20170523182026_CIT0002) (2013); 4 Gao ( key 20170523182026_CIT0010) (2011); 19 Mathew ( key 20170523182026_CIT0022) (2012); 26 Maes ( key 20170523182026_CIT0019) (1997); 42 Holst ( key 20170523182026_CIT0015) (2009); 150 Porsolt ( key 20170523182026_CIT0035) (1977); 229 Holst ( key 20170523182026_CIT0014) (2007); 148 Ranjbar ( key 20170523182026_CIT0036) (2013); 8 McKee ( key 20170523182026_CIT0023) (1997); 46 Chorin ( key 20170523182026_CIT0003) (2011); 31 Dwivedi ( key 20170523182026_CIT0005) (2003); 60 Watanabe ( key 20170523182026_CIT0048) (2010); 56 Fava ( key 20170523182026_CIT0008) (2008); 165 Swardfager ( key 20170523182026_CIT0042) 2013; 37 Depoortere ( key 20170523182026_CIT0004) (2012); 12 Ishitobi ( key 20170523182026_CIT0016) (2012); 72 Szewczyk ( key 20170523182026_CIT0043) (2011); 35 Młyniec ( key 20170523182026_CIT0029) (2012); 64 Młyniec ( key 20170523182026_CIT0030) (2013); 62 Malkesman ( key 20170523182026_CIT0021) (2012); 15 Młyniec ( key 20170523182026_CIT0025) 2013; 65 Jackson ( key 20170523182026_CIT0017) (2006); 17 Skolnick ( key 20170523182026_CIT0039) (2002); 23 Lara ( key 20170523182026_CIT0018) (2013); 16 Popovics ( key 20170523182026_CIT0034) (2011); 68 Tassabehji ( key 20170523182026_CIT0046) (2008); 95 23683309 - Int J Neuropsychopharmacol. 2013 Oct;16(9):2111-7 12912764 - Arch Gen Psychiatry. 2003 Aug;60(8):804-15 24333148 - Neuropharmacology. 2014 Apr;79:290-7 8827185 - Psychiatr Clin North Am. 1996 Jun;19(2):179-200 24512471 - J Recept Signal Transduct Res. 2014 Aug;34(4):307-12 23806573 - Biol Psychiatry. 2013 Dec 15;74(12):872-8 24409146 - Front Pharmacol. 2013 Dec 27;4:161 22192464 - Neurosci Res. 2012 Mar;72(3):257-62 24818801 - Expert Opin Investig Drugs. 2014 Sep;23(9):1181-92 19463882 - Neurochem Int. 2009 Dec;55(7):536-41 19213833 - Endocrinology. 2009 Jun;150(6):2577-85 23474197 - Neurochem Int. 2013 Jun;62(7):936-9 24130605 - Iran J Psychiatry. 2013 Jun;8(2):73-9 24948052 - Pharmacol Rep. 2014 Aug;66(4):534-44 17885920 - J Recept Signal Transduct Res. 2007;27(4):235-46 20812023 - Cell Mol Life Sci. 2011 Jan;68(1):85-95 19931332 - Neurochem Int. 2010 Feb;56(3):410-6 15891778 - Nat Rev Neurosci. 2005 Jun;6(6):449-62 23567517 - Neurosci Biobehav Rev. 2013 Jun;37(5):911-29 22610492 - Metallomics. 2012 Jul;4(7):614-8 12373530 - Amino Acids. 2002;23(1-3):153-9 9276075 - Biol Psychiatry. 1997 Sep 1;42(5):349-58 24103211 - Int J Neuropsychopharmacol. 2014 Feb;17(2):331-6 18975044 - Amino Acids. 2009 Jan;36(1):147-58 21906419 - Int J Neuropsychopharmacol. 2012 Sep;15(8):1135-48 21900570 - J Neurosci. 2011 Sep 7;31(36):12916-26 15383539 - J Biol Chem. 2004 Dec 17;279(51):53806-17 22303887 - CNS Drugs. 2012 Mar 1;26(3):189-204 19837463 - Trends Pharmacol Sci. 2009 Nov;30(11):563-9 15123501 - Br J Psychiatry. 2004 May;184:386-92 23950580 - Pharmacol Rep. 2013;65(3):579-92 10701476 - J Affect Disord. 1999 Dec;56(2-3):189-94 23453290 - Biol Psychiatry. 2013 Jun 15;73(12):1125-32 18655800 - Physiol Behav. 2008 Oct 20;95(3):365-9 22661173 - Pharmacol Rep. 2012;64(2):249-55 16959833 - Endocrinology. 2007 Jan;148(1):13-20 22814010 - Pharmacol Rep. 2012;64(3):567-75 24552999 - Pharmacol Rep. 2013;65(6):1512-8 22884904 - Curr Opin Pharmacol. 2012 Dec;12(6):647-52 9441746 - Genomics. 1997 Dec 15;46(3):426-34 18172020 - Am J Psychiatry. 2008 Mar;165(3):342-51 16271821 - Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1201-13 23089648 - Behav Brain Res. 2013 Feb 1;238:30-5 16708020 - Neuroreport. 2006 May 29;17(8):813-6 17488974 - Mol Endocrinol. 2007 Jul;21(7):1685-98 20156515 - Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):693-701 20593259 - Neurotox Res. 2011 May;19(4):584-91 19261885 - J Neurosci. 2009 Mar 4;29(9):2890-901 16978443 - Int J Neuropsychopharmacol. 2007 Oct;10(5):621-9 15567428 - Neuropharmacology. 2004 Dec;47(8):1189-97 596982 - Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36
References_xml	– volume: 95 start-page: 365 year: (2008) ident: key 20170523182026_CIT0046 article-title: Zinc deficiency induces depression-like symptoms in adult rats publication-title: Physiol Behav doi: 10.1016/j.physbeh.2008.06.017 – volume: 42 start-page: 349 year: (1997) ident: key 20170523182026_CIT0019 article-title: Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(96)00365-4 – volume: 17 start-page: 813 year: (2006) ident: key 20170523182026_CIT0017 article-title: GPR39 receptor expression in the mouse brain publication-title: Neuroreport doi: 10.1097/01.wnr.0000215779.76602.93 – start-page: 1 year: (2014) ident: key 20170523182026_CIT0033 article-title: NMDA antagonists under investigation for the treatment of major depressive disorder publication-title: Expert Opin Investig Drugs – volume: 17 start-page: 331 year: (2014) ident: key 20170523182026_CIT0011 article-title: Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145713001119 – volume: 35 start-page: 693 year: (2011) ident: key 20170523182026_CIT0043 article-title: The role of zinc in neurodegenerative inflammatory pathways in depression publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2010.02.010 – volume: 150 start-page: 2577 year: (2009) ident: key 20170523182026_CIT0015 article-title: G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction publication-title: Endocrinology doi: 10.1210/en.2008-1250 – volume: 68 start-page: 85 year: (2011) ident: key 20170523182026_CIT0034 article-title: GPR39: a Zn(2+)-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions publication-title: Cell Mol Life Sci doi: 10.1007/s00018-010-0517-1 – volume: 26 start-page: 189 year: (2012) ident: key 20170523182026_CIT0022 article-title: Ketamine for treatment-resistant unipolar depression: current evidence publication-title: CNS Drugs doi: 10.2165/11599770-000000000-00000 – volume: 74 start-page: 872 year: 2013 ident: key 20170523182026_CIT0041 article-title: Zinc in depression: a meta-analysis publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2013.05.008 – volume: 19 start-page: 179 year: (1996) ident: key 20170523182026_CIT0007 article-title: Definition and epidemiology of treatment-resistant depression publication-title: Psychiatr Clin North Am doi: 10.1016/S0193-953X(05)70283-5 – volume: 16 start-page: 2111 year: (2013) ident: key 20170523182026_CIT0018 article-title: Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145713000485 – volume: 65 start-page: 1512 year: (2013) ident: key 20170523182026_CIT0038 article-title: Zinc as a marker of affective disorders publication-title: Pharmacol Rep doi: 10.1016/S1734-1140(13)71512-3 – volume: 60 start-page: 804 year: (2003) ident: key 20170523182026_CIT0005 article-title: Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.60.8.804 – volume: 4 start-page: 534 year: 2014 ident: key 20170523182026_CIT0027 article-title: Essential elements in depression and anxiety. Part I publication-title: Pharmacol Rep doi: 10.1016/j.pharep.2014.03.001 – volume: 36 start-page: 147 year: (2009) ident: key 20170523182026_CIT0049 article-title: Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice publication-title: Amino Acids doi: 10.1007/s00726-008-0195-6 – volume: 29 start-page: 2890 year: (2009) ident: key 20170523182026_CIT0001 article-title: Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus publication-title: J Neurosci doi: 10.1523/JNEUROSCI.5093-08.2009 – volume: 64 start-page: 249 year: (2012) ident: key 20170523182026_CIT0029 article-title: Zinc deficiency induces behavioral alterations in the tail suspension test in mice. Effect of antidepressants publication-title: Pharmacol Rep doi: 10.1016/S1734-1140(12)70762-4 – volume: 4 start-page: 614 year: (2012) ident: key 20170523182026_CIT0044 article-title: Proposed glucocorticoid-mediated zinc signaling in the hippocampus publication-title: Metallomics doi: 10.1039/c2mt20018j – volume: 238 start-page: 30 year: 2013 ident: key 20170523182026_CIT0026 article-title: The role of the GPR39 receptor in zinc deficient-animal model of depression publication-title: Behav. Brain Res doi: 10.1016/j.bbr.2012.10.020 – volume: 165 start-page: 342 year: (2008) ident: key 20170523182026_CIT0008 article-title: Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2007.06111868 – volume: 37 start-page: 911 year: 2013 ident: key 20170523182026_CIT0042 article-title: Potential roles of zinc in the pathophysiology and treatment of major depressive disorder publication-title: Neurosci Biobehav Rev doi: 10.1016/j.neubiorev.2013.03.018 – volume: 10 start-page: 621 year: (2007) ident: key 20170523182026_CIT0031 article-title: Cyclic AMP response element-binding protein in post-mortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145706007231 – volume: 29 start-page: 1201 year: (2005) ident: key 20170523182026_CIT0012 article-title: Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2005.08.006 – volume: 64 start-page: 567 year: (2012) ident: key 20170523182026_CIT0024 article-title: Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test publication-title: Pharmacol Rep doi: 10.1016/S1734-1140(12)70852-6 – volume: 12 start-page: 647 year: (2012) ident: key 20170523182026_CIT0004 article-title: GI functions of GPR39: novel biology publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2012.07.019 – volume: 21 start-page: 1685 year: (2007) ident: key 20170523182026_CIT0006 article-title: GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue publication-title: Mol Endocrinol doi: 10.1210/me.2007-0055 – volume: 65 start-page: 579 year: 2013 ident: key 20170523182026_CIT0025 article-title: Zinc deficiency alters responsiveness to antidepressant drugs in mice publication-title: Pharmacol Rep doi: 10.1016/S1734-1140(13)71035-1 – volume: 19 start-page: 584 year: (2011) ident: key 20170523182026_CIT0010 article-title: Disruption of the CaMKII/CREB signaling is associated with zinc deficiency-induced learning and memory impairments publication-title: Neurotox Res doi: 10.1007/s12640-010-9206-y – volume: 72 start-page: 257 year: (2012) ident: key 20170523182026_CIT0016 article-title: Administration of antisense DNA for GPR39-1b causes anxiolytic-like responses and appetite loss in rats publication-title: Neurosci Res doi: 10.1016/j.neures.2011.12.002 – volume: 79 start-page: 290 year: 2014 ident: key 20170523182026_CIT0028 article-title: The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2013.12.001 – volume: 6 start-page: 449 year: (2005) ident: key 20170523182026_CIT0009 article-title: The neurobiology of zinc in health and disease publication-title: Nat Rev Neurosci doi: 10.1038/nrn1671 – volume: 27 start-page: 235 year: (2007) ident: key 20170523182026_CIT0050 article-title: Isolation of Zn2+ as an endogenous agonist of GPR39 from fetal bovine serum publication-title: J Recept Signal Transduct Res doi: 10.1080/10799890701506147 – volume: 229 start-page: 327 year: (1977) ident: key 20170523182026_CIT0035 article-title: Behavioral despair in mice: a primary screening test for antidepressants publication-title: Arch Int Pharmacodyn thérapie – volume: 4 start-page: 161 year: (2013) ident: key 20170523182026_CIT0002 article-title: Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants publication-title: Front Pharmacol doi: 10.3389/fphar.2013.00161 – volume: 56 start-page: 410 year: (2010) ident: key 20170523182026_CIT0048 article-title: Susceptibility to stress in young rats after 2-week zinc deprivation publication-title: Neurochem Int doi: 10.1016/j.neuint.2009.11.014 – volume: 23 start-page: 153 year: (2002) ident: key 20170523182026_CIT0039 article-title: Modulation of glutamate receptors: strategies for the development of novel antidepressants publication-title: Amino Acids doi: 10.1007/s00726-001-0121-7 – volume: 47 start-page: 1189 year: (2004) ident: key 20170523182026_CIT0037 article-title: Magnesium-deficient diet alters depression- and anxiety-related behavior in mice--influence of desipramine and Hypericum perforatum extract publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2004.08.010 – volume: 30 start-page: 563 year: (2009) ident: key 20170523182026_CIT0040 article-title: Glutamate-based antidepressants: 20 years on publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2009.09.002 – volume: 279 start-page: 53806 year: (2004) ident: key 20170523182026_CIT0013 article-title: Common structural basis for constitutive activity of the ghrelin receptor family publication-title: J Biol Chem doi: 10.1074/jbc.M407676200 – volume: 31 start-page: 12916 year: (2011) ident: key 20170523182026_CIT0003 article-title: Upregulation of KCC2 activity by zinc-mediated neurotransmission via the mZnR/GPR39 receptor publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2205-11.2011 – volume: 184 start-page: 386 year: (2004) ident: key 20170523182026_CIT0047 article-title: Global burden of depressive disorders in the year 2000 publication-title: Br J Psychiatry doi: 10.1192/bjp.184.5.386 – volume: 55 start-page: 536 year: (2009) ident: key 20170523182026_CIT0045 article-title: Behavior in the forced swim test and neurochemical changes in the hippocampus in young rats after 2-week zinc deprivation publication-title: Neurochem Int doi: 10.1016/j.neuint.2009.05.011 – volume: 73 start-page: 1125 year: (2013) ident: key 20170523182026_CIT0032 article-title: Glutamate-based antidepressants: preclinical psychopharmacology publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2013.01.021 – volume: 9893 start-page: 1 year: (2014) ident: key 20170523182026_CIT0051 article-title: GPR39-1b, the 5-transmembrane isoform of GPR39 interacts with neurotensin receptor NTSR1 and modifies its function publication-title: J Recept Signal Transduct Res – volume: 46 start-page: 426 year: (1997) ident: key 20170523182026_CIT0023 article-title: Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors publication-title: Genomics doi: 10.1006/geno.1997.5069 – volume: 56 start-page: 189 year: (1999) ident: key 20170523182026_CIT0020 article-title: Lower serum zinc in major depression in relation to changes in serum acute phase proteins publication-title: J Affect Disord doi: 10.1016/S0165-0327(99)00011-7 – volume: 15 start-page: 1135 year: (2012) ident: key 20170523182026_CIT0021 article-title: Acute D-serine treatment produces antidepressant-like effects in rodents publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145711001386 – volume: 148 start-page: 13 year: (2007) ident: key 20170523182026_CIT0014 article-title: GPR39 signaling is stimulated by zinc ions but not by obestatin publication-title: Endocrinology doi: 10.1210/en.2006-0933 – volume: 8 start-page: 73 year: (2013) ident: key 20170523182026_CIT0036 article-title: Effects of zinc supplementation in patients with major depression: a randomized clinical trial publication-title: Iran J Psychiatry – volume: 62 start-page: 936 year: (2013) ident: key 20170523182026_CIT0030 article-title: GPR39 up-regulation after selective antidepressants publication-title: Neurochem Int doi: 10.1016/j.neuint.2013.02.024 – reference: 17488974 - Mol Endocrinol. 2007 Jul;21(7):1685-98 – reference: 21900570 - J Neurosci. 2011 Sep 7;31(36):12916-26 – reference: 19837463 - Trends Pharmacol Sci. 2009 Nov;30(11):563-9 – reference: 19213833 - Endocrinology. 2009 Jun;150(6):2577-85 – reference: 24333148 - Neuropharmacology. 2014 Apr;79:290-7 – reference: 23567517 - Neurosci Biobehav Rev. 2013 Jun;37(5):911-29 – reference: 23950580 - Pharmacol Rep. 2013;65(3):579-92 – reference: 20812023 - Cell Mol Life Sci. 2011 Jan;68(1):85-95 – reference: 9441746 - Genomics. 1997 Dec 15;46(3):426-34 – reference: 15567428 - Neuropharmacology. 2004 Dec;47(8):1189-97 – reference: 23453290 - Biol Psychiatry. 2013 Jun 15;73(12):1125-32 – reference: 18975044 - Amino Acids. 2009 Jan;36(1):147-58 – reference: 19463882 - Neurochem Int. 2009 Dec;55(7):536-41 – reference: 16959833 - Endocrinology. 2007 Jan;148(1):13-20 – reference: 16708020 - Neuroreport. 2006 May 29;17(8):813-6 – reference: 20156515 - Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):693-701 – reference: 24818801 - Expert Opin Investig Drugs. 2014 Sep;23(9):1181-92 – reference: 16271821 - Prog Neuropsychopharmacol Biol Psychiatry. 2005 Dec;29(8):1201-13 – reference: 15123501 - Br J Psychiatry. 2004 May;184:386-92 – reference: 24103211 - Int J Neuropsychopharmacol. 2014 Feb;17(2):331-6 – reference: 19931332 - Neurochem Int. 2010 Feb;56(3):410-6 – reference: 23089648 - Behav Brain Res. 2013 Feb 1;238:30-5 – reference: 17885920 - J Recept Signal Transduct Res. 2007;27(4):235-46 – reference: 18655800 - Physiol Behav. 2008 Oct 20;95(3):365-9 – reference: 16978443 - Int J Neuropsychopharmacol. 2007 Oct;10(5):621-9 – reference: 12912764 - Arch Gen Psychiatry. 2003 Aug;60(8):804-15 – reference: 10701476 - J Affect Disord. 1999 Dec;56(2-3):189-94 – reference: 596982 - Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36 – reference: 24409146 - Front Pharmacol. 2013 Dec 27;4:161 – reference: 8827185 - Psychiatr Clin North Am. 1996 Jun;19(2):179-200 – reference: 22303887 - CNS Drugs. 2012 Mar 1;26(3):189-204 – reference: 22192464 - Neurosci Res. 2012 Mar;72(3):257-62 – reference: 18172020 - Am J Psychiatry. 2008 Mar;165(3):342-51 – reference: 24512471 - J Recept Signal Transduct Res. 2014 Aug;34(4):307-12 – reference: 24130605 - Iran J Psychiatry. 2013 Jun;8(2):73-9 – reference: 21906419 - Int J Neuropsychopharmacol. 2012 Sep;15(8):1135-48 – reference: 22884904 - Curr Opin Pharmacol. 2012 Dec;12(6):647-52 – reference: 23683309 - Int J Neuropsychopharmacol. 2013 Oct;16(9):2111-7 – reference: 22661173 - Pharmacol Rep. 2012;64(2):249-55 – reference: 23474197 - Neurochem Int. 2013 Jun;62(7):936-9 – reference: 19261885 - J Neurosci. 2009 Mar 4;29(9):2890-901 – reference: 15383539 - J Biol Chem. 2004 Dec 17;279(51):53806-17 – reference: 9276075 - Biol Psychiatry. 1997 Sep 1;42(5):349-58 – reference: 12373530 - Amino Acids. 2002;23(1-3):153-9 – reference: 24948052 - Pharmacol Rep. 2014 Aug;66(4):534-44 – reference: 15891778 - Nat Rev Neurosci. 2005 Jun;6(6):449-62 – reference: 22610492 - Metallomics. 2012 Jul;4(7):614-8 – reference: 20593259 - Neurotox Res. 2011 May;19(4):584-91 – reference: 23806573 - Biol Psychiatry. 2013 Dec 15;74(12):872-8 – reference: 22814010 - Pharmacol Rep. 2012;64(3):567-75 – reference: 24552999 - Pharmacol Rep. 2013;65(6):1512-8
SSID	ssj0024536
Score	2.3980072
Snippet	Background:Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.Methods:In the present study, we... Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors. In the present study, we investigated... Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.BACKGROUNDZinc may act as a neurotransmitter... Background: Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors. Methods: In the present study,...
SourceID	pubmedcentral proquest pubmed crossref oup
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1
SubjectTerms	Animals Anxiety Brain-derived neurotrophic factor Brain-Derived Neurotrophic Factor - metabolism Corticosterone - blood CREB-Binding Protein - metabolism Dark Adaptation - genetics Depression - genetics Depression - metabolism Depression - pathology Disease Models, Animal Down-Regulation - genetics Hindlimb Suspension Hippocampus - metabolism Hypothalamus Immobility Response, Tonic - physiology Kinases Male Mental depression Mice Mice, Inbred C57BL Mice, Knockout Motor Activity - genetics Proteins Receptor, trkB - metabolism Receptors, G-Protein-Coupled - deficiency Receptors, G-Protein-Coupled - genetics Swimming - psychology Time Factors Zinc - metabolism
Title	GPR39 (Zinc Receptor) Knockout Mice Exhibit Depression-Like Behavior and CREB/BDNF Down-Regulation in the Hippocampus
URI	https://www.ncbi.nlm.nih.gov/pubmed/25609596 https://www.proquest.com/docview/3170125860 https://www.proquest.com/docview/1655256695 https://www.proquest.com/docview/1765970297 https://pubmed.ncbi.nlm.nih.gov/PMC4360246
Volume	18
WOSCitedRecordID	wos000352535900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1469-5111 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024536 issn: 1461-1457 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVASL databaseName: Oxford Journals Open Access Collection customDbUrl: eissn: 1469-5111 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024536 issn: 1461-1457 databaseCode: TOX dateStart: 19980701 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1469-5111 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0024536 issn: 1461-1457 databaseCode: 7X7 dateStart: 19980701 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1469-5111 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0024536 issn: 1461-1457 databaseCode: BENPR dateStart: 19980701 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1469-5111 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0024536 issn: 1461-1457 databaseCode: M2M dateStart: 19980701 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1469-5111 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0024536 issn: 1461-1457 databaseCode: PIMPY dateStart: 19980701 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYLgcuvB-FpRhptQK0VvOyU58Q3bYsgpaoWqTCJUpsB8LDDU0D6r9n3DjtFqFeuERKPAdH4xl_Mx5_g9AxIATKpZTEYzwkAXcCArGKR1TqiMx3lfCTbN1sIpxMerMZj2zCrbRllY1PXDtqORcmR971DXG4R3vMeVn8JKZrlDldtS00DtChYSoLWuiwP5xE0y3bHvXt_SKXuAEN7Q09COO7-VdddItV1WRUmj1p557bJbj5d9XkpW1odON_f-Amum4BKH5Vr5hb6IrSt9FJVDNYr07xxfZCVnmKT3C05bZe3UHV62jqc_zsU64FBsipCojZn-O3GtzqvFriMfgdPDRNt_MlHjRVtpq8y78pbLkYFzjREp9Nh_1ufzAZ4cH8tyZT9dk2EsO5xoBK8XleFLDR_iiq8i76MBpenJ0T27mBCObwJZEySzMAnixwFEsC0Dr3Usmp9KTifk_wlKlM-k7mOkmYAeYLwbEYbwMBKlOJ8u-hlp5r9QBhKaSgLkRVNPUCEXgp4C8v64UCnA9VzG-jF43uYmFpzU13je9xfbzux0bRca3oNjreCBc1m8e_xZ7AItgvcdQoObZGX8ZbDbfR080wmKs5g0m0mldl7DJKAWUyTvfIhGA_oekq1kb36zW3mYtBqJxy1kbhzmrcCBi68N0RnX9Z04YHPgODYA_3T_0RugaYkNaF6UeotVxU6jG6Kn4t83LRQQfhLFw_ex1ra511GgOeY28M36I34-gjvF28n_0BlAc4Mg
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwELaWBQkuvB-FhTXSsgK0UZM4duoDQuy2pas-VFVFWnEJie1AeDihTVj1T_EbGTdJu0Wotz1w9iiykm_G38Qz8yF0AAyBciml5TLuWx63PQtyFddSkS1i4ihBwngpNuGPRq2zMz7eQb_rXhhTVlnHxGWglqkw_8ibxAwOd2mL2W-zn5ZRjTK3q7WERgmLvlqcQ8o2f3Pahu_7wnW7nelJz6pUBSzBbJ5bUsZRDKSIebZioQc74m4kOZWuVJy0BI-YiiWxY8cO_Rj4iA-gN54AyRNToSLw3CvoqgeZkJGKGLrD9Ww_SqpuJsdyPOpX_YA2J83kq86a2aKo_9_UJ-BGV90Fcvt3jeaFQ6976397XbfRzYpe43elP9xBO0rfRYfjcj734ghP1-1m8yN8iMfryd2Le6h4P54Qjl9-TLTAQKhVlqezV7iv4dBIixwPIarijpEUT3LcrmuItTVIvilcTZqc4VBLfDLpHDeP26Mubqfn2pqoz5VMGk40Bs6Ne0mWAY34kRXz--jDpbySB2hXp1o9QlgKKagDOSONXE94bgTs0o1bvoDQShUjDfS6xkogqqHtRjvke1AWD5DAACsogdVAByvjrJxV8m-zfQDddou9GlRBFdLmwRpRDfR8tQzByNwwhVqlxTxwGKXAoRmnW2x8iA6-0UxroIclxld7MfybU84ayN9A_8rADEPfXNHJl-VQdI8wcED2ePvW99H13nQ4CAano_4TdAPYLy1L8PfQbj4r1FN0TfzKk_ns2dKzMfp02b7xB7K9jZU
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GPR39+%28Zinc+Receptor%29+Knockout+Mice+Exhibit+Depression-Like+Behavior+and+CREB%2FBDNF+Down-Regulation+in+the+Hippocampus&rft.jtitle=The+international+journal+of+neuropsychopharmacology&rft.au=Mlyniec%2C+Katarzyna&rft.au=Budziszewska%2C+Boguslawa&rft.au=Holst%2C+Birgitte&rft.au=Ostachowicz%2C+Beata&rft.date=2015-02-01&rft.issn=1461-1457&rft.eissn=1469-5111&rft.volume=18&rft.issue=3&rft.spage=1&rft.epage=8&rft_id=info:doi/10.1093%2Fijnp%2Fpyu002&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1461-1457&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1461-1457&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1461-1457&client=summon